Navigation Links
OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
Date:9/30/2009

ry promising results, as standard platinum, 5-FU, and radiation-based regimens for this disease are accompanied by a high incidence of severe radiation esophagitis, requiring patients to receive nutrition through feeding tubes," said Dr. Safran. "Paclitaxel poliglumex's selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects we have observed in this phase 2 study. Our results justify proceeding to a randomized, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Dr. Safran added.

"We look forward to discussing with the Food and Drug Administration a potential phase III registration strategy for this indication," said Jack Singer, M.D., Chief Medical Officer at CTI. "This would be the first registration study for a radiation sensitizing agent in this indication."

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Ph
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
3. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
6. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
7. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
10. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
(Date:9/20/2014)... September 20, 2014 The excitement is building up ... Airy, North Carolina. This year the Surry Arts Council will ... from around the country who are still fans of the Andy ... a sitcom that aired on CBS from 1960 through 1968. ... in American television history. Mount Airy, North Carolina is where ...
(Date:9/20/2014)... 20, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has launched a special offer ... prom outfits are popular among worldwide clients. Now, all ... prom dresses on its website. , Additionally, ... from around the world. Great custom made items can ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2
... , , WEST PALM BEACH, ... leading providers of he a ring aids ... a hearing care program designed exclusively for AARP members. The program is scheduled ... October and will eventually be extended to AARP members in all 50 states ...
... , , , , ... Services, Inc. (NYSE: WST ) today announced that William Federici, ... Investor Relations, will be attending the Ninth Annual CJS Securities "New Ideas" ... , , While there will be no formal presentation ...
... , , OKLAHOMA CITY, ... leading provider for revenue cycle management solutions for the ... with the Financial Services Accreditation Program (FSAP) - Electronic ... Commission (EHNAC). EHNAC FSAP-EHN accreditation demonstrates that the organization ...
... Survey seeks feedback from public to help redesign ... Aug. 11 Participate in the American Dental Association (ADA) Web-based survey at ... to win a $150 Amazon.com gift certificate and, at the same time, help ... news and information on hundreds of dental topics, ranging from basic dental care ...
... , PALO ALTO, Calif., Aug. 11 Jazz Pharmaceuticals, ... second quarter ended June 30, 2009. , , Total ... for the quarter ended June 30, 2008. Revenues for the second quarter ... received in July 2008 and recognized as revenue when the last patient ...
... , ATLANTA, Aug. 11 Sean Carroll, CEO of Atlanta-based ... been appointed to serve as a board member of the philanthropic and ... M A ). The AHIMA Fo ... a non-profit organization that provides development, research and scholarships for health information ...
Cached Medicine News:Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 4Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 2Health News:Revenue Management Solutions, LLC Receives EHNAC Financial Services Accreditation 3Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 2Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 3Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 4Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 5Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 6Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 7Health News:Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 8Health News:Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Medicine Products: